Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Regulatory News (BQE)

  • There is currently no data for BQE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Bioquell PLC

22 May 2015 07:47

RNS Number : 0212O
Bioquell PLC
22 May 2015
 



FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Bioquell PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Bioquell PLC

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

22 May 2015

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

10p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

-

Nil

-

(2) Cash-settled derivatives:

 

Nil

-

Nil

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

-

Nil

-

 

TOTAL:

Nil

-

Nil

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a. Interests of directors of Bioquell PLC (and persons presumed to be acting in

concert with the directors) in its ordinary shares

 

Director

Number of ordinary shares

% of issued share capital

Nigel Keen(1)

127,270

0.3%

Nicholas Adams

485,599

1.1%

Michael Roller

19,245

-%

Simon Constantine

120,634

0.3%

Christopher Mills(2)

12,610,000

29.6%

 

(1) Nigel Keen holds his interests jointly with his wife, Caroline Keen

(2) Christopher Mills is Chief Investment Officer and a member of Harwood Capital LLP which owns 29.6% of the issued share capital in Bioquell PLC

 

b. Interests of close relatives of directors of Bioquell PLC in its ordinary shares

 

Name

Relation to Director

Number of ordinary shares

% of issued share capital

Caroline Keen(1)

Wife of Nigel Keen

127,270

0.3%

Letitia Adams

Wife of Nicholas Adams

514,979

1.2%

Joanna Constantine

Wife of Simon Constantine

349,366

0.8%

 

(1) Caroline Keen holds her interests jointly with her husband, Nigel Keen

 

c. Options and awards held by directors of Bioquell PLC (and persons assumed

to be acting in concert with the directors) in its ordinary shares

 

(i) Executive Share Option Share Scheme

 

Director

Number of Shares under option

Option Price (pence)

Date from which exercisable

Nicholas Adams

194,000

146.5

19 April 2016

Nicholas Adams

232,000

128.0

24 March 2017

Nicholas Adams

254,000

120.5

26 March 2018

Michael Roller

150,000

128.0

24 March 2017

Michael Roller

159,000

120.5

26 March 2018

 

d. Interests in Bioquell PLC held by other concert parties in its ordinary shares

 

Name

Number of ordinary shares

% of issued share capital

Harwood Capital LLP

12,610,000

29.6%

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

22 May 2015

Contact name:

Michael Roller

Telephone number:

+44 (0)1264 835 817

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEDMGZKVZNGKZG
Date   Source Headline
11th Apr 201410:57 amRNSHolding(s) in Company
8th Apr 20147:00 amRNSAnnual Financial Report
2nd Apr 201411:26 amRNSDirector/PDMR Shareholding
28th Mar 201412:38 pmRNSDirector/PDMR Shareholding
18th Mar 20147:00 amRNSAnnual Financial Report
21st Jan 20147:00 amRNSAppointment of Director
17th Jan 20147:00 amRNSPre-close Update
13th Dec 20137:00 amRNSDirector/PDMR Shareholding
12th Dec 20138:25 amRNSDirector/PDMR Shareholding
15th Nov 20137:00 amRNSInterim Management Statement
6th Nov 20132:36 pmRNSBlocklisting Interim Review
23rd Oct 20134:55 pmRNSHolding(s) in Company
26th Sep 20137:00 amRNSDirectorate Change
28th Aug 20137:00 amRNSHalf Yearly Report
13th Aug 20134:23 pmRNSHolding(s) in Company
8th Aug 20134:49 pmRNSNew Directorship of Non-Executive Director
26th Jun 20135:11 pmRNSHolding(s) in Company
26th Jun 201310:53 amRNSHolding(s) in Company
25th Jun 20132:40 pmRNSHolding(s) in Company
24th Jun 20133:04 pmRNSHolding(s) in Company
24th Jun 201311:21 amRNSHolding(s) in Company
13th May 20135:41 pmRNSResult of AGM
13th May 20137:00 amRNSInterim Management Statement
8th May 20139:44 amRNSBlocklisting Interim Review
25th Apr 20138:50 amRNSDirector/PDMR Shareholding
11th Apr 20138:22 amRNSAnnual Financial Report
19th Mar 20137:00 amRNSAnnual Financial Report
21st Jan 20132:29 pmRNSHolding(s) in Company
14th Jan 20137:00 amRNSPre-close update
18th Dec 20127:00 amRNSNew Director
16th Nov 20127:00 amRNSInterim Management Statement
1st Nov 201212:16 pmRNSNew directorship of non-executive director
29th Aug 20127:00 amRNSHalf Yearly Report
9th Jul 201211:25 amRNSHolding(s) in Company
6th Jul 201212:57 pmRNSHolding(s) in Company
5th Jul 201212:16 pmRNSHolding(s) in Company
5th Jul 201210:49 amRNSHolding(s) in Company
2nd Jul 20123:15 pmRNSHolding(s) in Company
24th May 201212:55 pmRNSHolding(s) in Company
24th May 201212:52 pmRNSHolding(s) in Company
21st May 20122:30 pmRNSHolding(s) in Company
15th May 20127:00 amRNSInterim Management Statement
14th May 20122:47 pmRNSResult of AGM
11th May 201211:57 amRNSHolding(s) in Company
11th May 20129:34 amRNSHolding(s) in Company
10th May 201212:19 pmRNSHolding(s) in Company
12th Apr 20128:24 amRNSAnnual Financial Report
29th Mar 201211:23 amRNSDirector/PDMR Shareholding
23rd Mar 201210:04 amRNSHolding(s) in Company
20th Mar 20127:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.